Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region

Antonio Vena 1,2,*, Giovanni Cenderello 3, Elisa Balletto 1, Laura Mezzogori 1, Alessandro Santagostino Barbone 1, Marco Berruti 1,2,3, Lorenzo Ball 4,5, Denise Battaglini 4,5, Alessandro Bonsignore 6, Chiara Dentone 1, Daniele Roberto Giacobbe 1,2, Tarek Kamal Eldin 7, Malgorzata Mikulska 1,2, Barbara Rebesco 8, Chiara Robba 4,5, Ambra Scintu 7, Andrea Stimamiglio 9, Lucia Taramasso 1, Paolo Pelosi 4,5, Stefania Artioli 7 and Matteo Bassetti 1,2

Abstract: Monoclonal antibodies, such as bamlanivimab and etesevimab combination (BEC), have been proposed for patients with mild or moderate coronavirus disease 2019 (COVID-19). However, few studies have assessed the factors associated with the early administration of BEC or the impact of early BEC treatment on the clinical evolution of the patients. We conducted a retrospective cohort study of all adults with COVID-19 who received BEC at three institutions in the Liguria region. The primary endpoint was to investigate the clinical variables associated with early BEC infusion. Secondary endpoints were 30-day overall mortality and the composite endpoint of requirement of hospital admission or need for supplemental oxygen during the 30-day follow-up period. A total of 127 patients (median age 70 years; 56.7% males) received BEC. Of those, 93 (73.2%) received early BEC. Early BEC was associated with lower likelihood of hospital admission or need for supplemental oxygen (OR 0.19, 0.06–0.65; p = 0.02) in contrast to those reporting fever at presentation (OR 0.26, 0.08–0.82; p = 0.03) in contrast to those reporting fever at presentation (OR 0.26, 0.08–0.82; p = 0.03). Five patients who received early BEC died during the follow-up period, but only one of them due to COVID-19-related causes. Early bamlanivimab and etesevimab combination was more frequently administered to patients with a high Charlson comorbidity index. Despite this, early BEC was associated with a lower rate of hospital admission or need for any supplementary oxygen compared to late administration. These results suggest that efforts should focus on encouraging early BEC use in patients with mild–moderate COVID-19 at risk for complications.

1 Infectious Diseases Unit, Ospedale Policlinico San Martino–IRCCS, 16132 Genoa, Italy; elisa.balletto@gmail.com (E.B.); lauramezzogori@yahoo.com (L.M.); alessantagostino117@gmail.com (A.S.B.); marco.berruti1@gmail.com (M.B.); chiara.dentone@hsanmartino.it (C.D.); daniele.roberto.giacobbe@gmail.com (D.R.G.); m.mikulska@unige.it (M.M.); taramasso.lucia@gmail.com (L.T.); matteo.bassetti@unige.it (M.B.)
2 Department of Health Sciences (DISDALL), University of Genoa, 16132 Genoa, Italy
3 Infectious Disease Unit, Ospedale Sanremo, Azienda Sanitaria Locale 1, 18038 Genoa, Italy; g.cenderello@asl1.liguria.it
4 Anesthesia and Intensive Care, Ospedale Policlinico San Martino-IRCCS, 16132 Genoa, Italy; Lorenzo.ball@unige.it (L.B.); battaglini.denise@gmail.com (D.B.); kiarobba@gmail.com (C.R.); ppelosi@hotmail.com (P.P.)
5 Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, 16132 Genoa, Italy
6 Department of Legal and Forensic Medicine, University of Genoa, 16132 Genoa, Italy; alessandro.bonsignore@unige.it
7 Infectious Diseases and Hepatology Unit, Sant’Andrea Hospital La Spezia, 19121 La Spezia, Italy; tarek.kamaleldin@asl5.liguria.it (T.K.E.); ambra.scintu@asl5.liguria.it (A.S.); stefania.artioli@asl5.liguria.it (S.A.)
8 Area Dipartimentale Sanitaria, Politiche del Farmaco, Azienda Ligure Sanitaria, A.Li.Sa., 16132 Genoa, Italy; Barbara.rebesco@regioneliguria.it
9 General Practitioner Azienda Sanitaria Locale 3 Genovese, 16165 Genoa, Italy; andrea.stimamiglio@gmail.com
* Correspondence: anton.vena@gmail.com; Tel.: +39-010-555-4658; Fax: +39-010-555-6712
Keywords: COVID-19; bamlanivimab; etesevimab; hospital admission

1. Introduction

Coronavirus disease 2019 (COVID-19) has resulted in a massive strain on healthcare infrastructures [1–4], with more than 350,000 patients requiring hospital admissions in the United States alone according to Center for Disease Control and Prevention (CDC) reports [5]. Older age [4,6], obesity [6,7] and certain medical conditions, such as hypertension, chronic obstructive pulmonary disease, chronic kidney disease or immunological disease, have been associated with higher disease severity and need for hospital admission [2–4,8,9].

Accordingly, there is need for effective and well-tolerated treatments that can halt the progression of COVID-19 at this early phase. Bamlanivimab and etesevimab are potent anti-spike neutralizing monoclonal antibodies that were derived from two separate patients who recovered from America and China, respectively [10,11]. Recent studies demonstrated that administering bamlanivimab and etesevimab combination (BEC) for mild-to-moderate COVID-19 reduces the viral load and duration of symptoms as well as possibly preventing hospitalizations [12,13].

The pathophysiology of COVID-19 suggests that inhibiting viral replication as early as possible after infection onset could possibly reduce the intensity of clinical symptoms [14,15]. Thus, our main objectives were to investigate (1) the clinical variables associated with the receipt of early BEC administration and (2) whether timely BEC administration resulted in any differences in hospital admission or other important outcomes among adults with COVID-19.

2. Materials and Methods

2.1. Study Design and Setting

This multicenter retrospective cohort study was performed across the three major tertiary hospitals of the Liguria region (San Martino Policlinico hospital, Sant’Andrea hospital and Sanremo hospital) between 18 March 2021 and 18 April 2021. These institutions serve approximately 700,000 inhabitants altogether, offer readily available infectious disease consultation services and are referral centers for COVID-19.

2.2. Inclusion Criteria

Non-hospitalized adults (aged ≥18 years) were eligible for inclusion if they (i) had a confirmed SARS-CoV-2 infection by polymerase chain reaction; (ii) had signs/symptoms attributable to COVID-19 for ≤10 days prior to the day of BEC infusion; (iii) received BEC for mild or moderate disease and (iv) had at least one characteristic (body mass index, BMI > 35 kg/m²) or underlying medical condition (renal failure requiring hemodialysis treatment; poorly controlled diabetes mellitus II, with glycated hemoglobin ≥75 mmol/mol or diabetes-related organ damage; primary or acquired immunodeficiency; cardiovascular disease, cerebrovascular disease, including hypertension with secondary organ damage; chronic obstructive pulmonary disease or other chronic pulmonary diseases) associated with an increased risk of severe COVID-19 [16]. Hospitalized patients were excluded from the present study unless they had been hospitalized for reasons other than COVID-19 (e.g., elective surgical procedure) and otherwise met all inclusion criteria.

2.3. Data Collection and Study Definitions

The following data were collected from the patients’ medical records at the baseline (i.e., at the time of BEC treatment): age in years; gender; underlying disease (both separately and summarized by means of the Charlson comorbidity index [17]); date of illness onset; signs and symptoms (fever, cough, shortness of breath, arthralgia–myalgia, asthenia, headache, diarrhea and ageusia or anosmia). As for clinical evolution, the following
variables were assessed during a 30-day follow-up period starting from BEC infusion: need for hospital admission, need for supplementary oxygen and survival status or death.

The date of illness onset was defined as the date when signs or symptoms related to disease were first noticed. Patients were considered to have mild COVID-19 if there was evidence of mild symptoms (e.g., fever, cough) without dyspnea [18]. Moderate illness was defined as clinical or radiological evidence of lower respiratory tract infection with oxygen saturation ≥94% [18]. According to the Authorization for Emergency Use (EUA) of monoclonal antibodies by the Food and Drug Administration (FDA), the following characteristics or underlying medical conditions were considered to be associated with an increased risk for severe illness from COVID-19: BMI ≥35 kg/m², chronic kidney disease, diabetes, ≥65 years of age, immunosuppressed, ≥55 years of age with cardiovascular disease (CVD), hypertension or chronic obstructive pulmonary disease (COPD)/chronic respiratory disease [16]. Supplemental oxygen use was defined as the delivery of oxygen by any modality, including nasal cannula, mask, non-invasive positive pressure ventilation or mechanical ventilation, and was recorded if sustained for >4 hours. Supplemental oxygen was administered per standardized clinical protocols at all centers only if patients presented PaO₂ <60 mmHg at rest in ambient air.

Secondary immunodeficiency was defined by the presence of an active solid or hematological cancer, solid organ or stem cell transplantation, HIV infection or autoimmune disease requiring immunosuppressive therapy.

Death was considered to be related to COVID-19 when (i) it resulted from a clinically compatible severe/critical COVID-19 illness, (ii) there was no clear alternative cause of death and (iii) there was no period of complete recovery between the illness and death.

2.4. Main Outcomes Measures

For all patients, follow-up ended 30 days after BEC infusion. Outcome data were obtained from the hospital medical charts or by a virtual visit performed by telephoning participants at their home. For the purpose of this study, the infusion of BEC within 5 days from illness onset was a priori (before starting the data analysis) considered an early treatment. The primary endpoint was to investigate the association between the receipt of an early BEC infusion and the clinical variables of the patients collected at the time of COVID-19 diagnosis. Secondary endpoints were 30-day overall mortality and the composite endpoint of requirement of hospital admission or need for supplemental oxygen during the 30-day follow-up period.

2.5. Infusion of Bamlanivimab and Etesevimab Combination

According to the manufacturer’s instruction, bamlanivimab and etesevimab were administered together as a single intravenous infusion; the authorized dose of 700 mg of bamlanivimab and 1400 mg of etesevimab was ensured for all patients [16]. No dose adjustment was required for patients with renal or hepatic impairment.

2.6. Statistical Analysis

Quantitative variables are expressed as median and interquartile range (IQR), and qualitative variables as number and percentage. Qualitative variables were compared using the χ² and Fisher’s exact tests, as appropriate. Quantitative variables were compared using the Wilcoxon rank sum test. Missing data for each variable were excluded from the denominator. Logistic regression was used (i) to determine the independent baseline patient-level factors (i.e., variables collected at the time of BEC infusion) associated with receipt of early BEC and (ii) to determine the association between early BEC and poor outcome. For all regression analyses, we first performed a univariate analysis in order to identify the association with each outcome of interest. Gender and sex were forced into each model. Variables with a p-value of ≤0.20 in each univariable analysis were retained in the final models if they remained significantly associated with the outcome at a p-value <0.05. Odds ratio (ORs) were estimated for logistic regressions, and 95% confidence
intervals (CIs) were estimated to evaluate the strengths of the association. Analyses were conducted using SPSS for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA).

2.7. Ethical Considerations

The study protocol was approved by the Ethics Committee of Liguria Region (N.CER Liguria 114/2020-ID10420). Written informed consent was provided by all participants in the study.

3. Results

During the study period, 127 patients with mild or moderate COVID-19 received treatment with bamlanivimab and etesevimab combination and were included in the present analysis. The clinical characteristics of the study population are shown in Table 1. The median (IQR) age was 70 (59–78), and 56.7% were males. The majority of patients had multiple comorbidities with a median (IQR) Charlson comorbidity index of 1 (0–2). Of these, 50.4% had a history of cardiovascular disease and 22.0% had chronic obstructive lung disease. Thirty-three patients (26.0%) had a BMI equal to or higher than 35 kg/m2. The most reported symptoms of COVID-19 illness at initial presentation were fever (59.8%), cough (50.4%) and asthenia (27.6%).

Table 1. Comparison of demographics and baseline clinical data between patients receiving early (n = 93) or late (n = 34) bamlanivimab and etesevimab combination therapy (univariate and multivariate analysis).

| Characteristics                  | Overall n = 127 (%) | Late Group n = 34 (%) | Early Group n = 93 (%) | p Value | OR (95% CI) | p Value |
|----------------------------------|--------------------|-----------------------|------------------------|---------|-------------|---------|
| Age, years                       | 70 (59–78)         | 69 (51–76)            | 71 (62–78)             | 0.18    | 1.21 (0.47–3.31) | 0.68    |
| Sex, male                        | 72 (56.7)          | 18 (52.9)             | 54 (58.1)              | 0.68    | 1.00 (0.97–1.04) | 0.65    |
| Comorbidities                    |                    |                       |                        |         |              |         |
| Cardiovascular disease           | 64 (50.4)          | 14 (41.2)             | 50 (53.8)              | 0.23    | -            |         |
| Obesity (BMI > 35)               | 33 (26.0)          | 8 (23.5)              | 25 (26.9)              | 0.82    | -            |         |
| Chronic obstructive lung disease | 28 (22.0)          | 4 (11.8)              | 24 (25.8)              | 0.14    | 2.75 (0.76–9.93) | 0.12    |
| Diabetes mellitus                | 22 (17.3)          | 5 (14.7)              | 17 (18.3)              | 0.79    | -            |         |
| Cerebrovascular disease          | 24 (18.9)          | 9 (26.5)              | 15 (16.1)              | 0.21    | -            |         |
| Secondary immunodeficiency       | 19 (15.0)          | 5 (14.7)              | 14 (15.1)              | 1.00    | -            |         |
| Chronic kidney disease           | 11 (8.7)           | 4 (11.8)              | 7 (7.5)                | 0.48    | -            |         |
| Charlson comorbidity index       | 1 (0–2)            | 0 (0–1)               | 1 (1–3)                | 0.003   | 1.60 (1.04–2.45) | 0.03    |
| McCabe Scale                     |                    |                       |                        |         |              |         |
| Non-fatal                        | 109 (85.4)         | 34 (100)              | 75 (80.6)              | 0.003   | -            |         |
| Ultimately fatal                 | 14 (11.0)          | 0                     | 14 (15.1)              | 0.02    | -            |         |
| Rapidly fatal                    | 4 (3.1)            | 0                     | 4 (4.3)                | 0.57    | -            |         |

BMI: Body Mass Index.

3.1. Comparison of Early Versus Late BEC

Almost three-quarters (75.6%) of all patients receiving BEC presented initially to the outpatient clinic, whereas the remaining patients received the monoclonal antibodies as inpatients because the diagnosis of COVID-19 was made during a hospitalization required for other medical reasons. Overall, the median time from symptoms onset to the BEC therapy was 4 days (IQR 2–6 days), with 93 patients (73.2%) receiving BEC within 5 days of symptoms onset. Of the remaining patients, 34 (26.8%) received treatment >5 days after symptoms onset. Univariate and multivariate analyses of factors associated with early BEC administration are outlined in Table 1. In the multivariate analysis, higher Charlson comorbidity index was the only factor associated with early BEC administration (OR 1.60, 95% CI 1.04–2.45; p = 0.03). Conversely, fever at presentation was inversely associated with early BEC (OR 0.26, 95% CI 0.08–0.82; p = 0.02).
3.2. Secondary Endpoints

In total, 19 out of 127 patients (15.0%) required hospital admission or supplemental oxygen during the 30-day follow-up period (Table 2). Factors associated with the need for hospital admission or supplemental oxygen in the univariate analysis (Table 3) were older age ($p = 0.02$), cerebrovascular disease ($p = 0.01$) and late BEC administration ($p = 0.01$). In the multivariate analysis (Table 3), early BEC remained the only factor associated with lower likelihood for hospital admission or need for supplemental oxygen (OR 0.19; 95% CI 0.06–0.65; $p = 0.008$). In contrast, shortness of breath at presentation was significantly associated with higher likelihood for hospital admission or need for supplemental oxygen (OR 5.58; 95% CI 1.03–30.45; $p = 0.04$).

Table 2. Comparison of care setting and clinical outcomes of patients receiving early ($n = 93$) or late ($n = 34$) bamlavinimab and etesevimab combination therapy.

| Characteristics                  | Overall $n = 127$ (%) | Late Group $n = 34$ (%) | Early Group $n = 93$ (%) | $p$ Value |
|----------------------------------|-----------------------|-------------------------|--------------------------|-----------|
| Care setting                     |                       |                         |                          |           |
| Outpatient clinic                | 96 (75.6)             | 31 (91.2)               | 65 (69.9)                | 0.18      |
| Hospital ward                    | 31 (24.4)             | 3 (8.8)                 | 28 (30.1)                |           |
| Need for hospital admission      | 10/97 (10.3)          | 7/31 (22.6)             | 3/66 (4.5)               | 0.01      |
| Need for supplemental oxygen     |                       |                         |                          |           |
| Any supplemental oxygen          | 17 (13.4)             | 9 (26.5)                | 8 (8.6)                  | 0.02      |
| Non-invasive positive pressure ventilation | 4 (3.1)           | 3 (8.8)                 | 1 (1.1)                  | 0.06      |
| Mechanical ventilation           | 0                     | 0                       | 0                        |           |
| Poor clinical outcome *          | 19 (15.0)             | 10 (24.9)               | 9 (9.7)                  | 0.01      |
| 30-day overall mortality         | 5 (3.9)               | 0                       | 5 (5.4)                  | 0.32      |

* For patients receiving BEC in an outpatient clinic, poor clinical outcome was observed in 7 out of 31 in the late group (22.6%) versus 4 out of 65 in the early group (6.2%, $p = 0.03$). For patients receiving BEC in the hospital ward poor clinical outcome was observed in 3 out of 3 (100%) patients in the late group versus 5 out of 28 patients in the early group (17.9%, $p = 0.01$).

Table 3. Univariate and multivariate analysis of factors associated with poor clinical outcome.

| Characteristics                  | Improvement $n = 108$ (%) | Poor Clinical Outcome $n = 19$ (%) | $p$ Value | OR (95% CI) | $p$ Value |
|----------------------------------|---------------------------|-----------------------------------|-----------|-------------|-----------|
| Age, years (median, IQR)         | 70 (57–76)                | 76 (68–83)                         | 0.02      | 1.03 (0.98–1.09) | 0.20      |
| Sex, male                        | 60 (55.6)                 | 12 (63.2)                          | 0.62      | 2.35 (0.71–7.77) | 0.16      |
| Underlying disease               |                           |                                   |           |             |           |
| Cardiovascular disease           | 53 (49.1)                 | 11 (57.9)                          | 0.62      |             |           |
| Obesity (BMI > 35)               | 31 (28.7)                 | 2 (10.5)                           | 0.15      | 0.45 (0.06–3.02) | 0.41      |
| Diabetes mellitus                | 18 (16.7)                 | 4 (21.1)                           | 0.74      |             |           |
| Chronic obstructive lung disease | 22 (20.4)                 | 6 (31.6)                           | 0.36      |             |           |
| Cerebrovascular disease          | 16 (14.8)                 | 8 (42.1)                           | 0.01      | 2.84 (0.84–9.63) | 0.09      |
| Chronic kidney disease           | 9 (8.3)                   | 2 (10.5)                           | 0.67      |             |           |
| Secondary immunodeficiency       | 17 (15.7)                 | 2 (10.5)                           | 0.73      |             |           |
| Charlson comorbidity index (median, IQR) | 1 (0–2)               | 1 (1–3)                            | 0.27      |             |           |
| McCabe Scale                     |                           |                                   |           |             |           |
| Non-fatal                        | 94 (87.0)                 | 15 (78.9)                          | 0.47      |             |           |
| Ultimately fatal                 | 12 (11.1)                 | 2 (10.5)                           | 1         |             |           |
| Rapidly fatal                    | 2 (1.9)                   | 2 (10.5)                           | 0.10      | 4.38 (0.42–45.06) | 0.21      |
Table 3. Cont.

| Characteristics                  | Improvement n = 108 (%) | Poor Clinical Outcome n = 19 (%) | p Value | OR (95% CI)    | p Value |
|----------------------------------|------------------------|---------------------------------|---------|----------------|---------|
| Signs and symptoms               |                        |                                 |         |                |         |
| Fever (Temperature > 37.3)       | 64 (59.3)              | 12 (63.2)                       | 0.80    |                |         |
| Cough                            | 53 (49.1)              | 11 (57.9)                       | 0.62    |                |         |
| Asthenia                         | 30 (27.8)              | 5 (26.3)                        | 1       |                |         |
| Headache                         | 19 (17.6)              | 3 (15.8)                        | 1       |                |         |
| Arthralgia-myalgia               | 18 (16.7)              | 1 (5.3)                         | 0.30    |                |         |
| Diarrhea                         | 8 (7.4)                | 3 (15.8)                        | 0.21    |                |         |
| Ageusia and anosmia              | 9 (8.3)                | 1 (5.3)                         | 1       |                |         |
| Dyspnœa                          | 6 (5.6)                | 3 (15.8)                        | 0.13    | 5.58 (1.03–30.45) | 0.04 |
| Early BEC (≤ 5 days)             | 84 (77.8)              | 9 (47.4)                        | 0.01    | 0.19 (0.06–0.65) | 0.008 |

BEC: Bamlanivimab and Etesevimab Combination.

After 30 days from BEC infusion, the overall mortality rate of the study population was 3.9% (5/127). All deceased patients acquired COVID-19 during their hospital stay because of other medical reasons. All of them received early BEC infusion, but only one death was considered to be COVID-19-related (Supplementary Table S1).

4. Discussion

These results suggest that bamlanivimab and etesevimab combination is effective for the treatment of patients with mild and moderate COVID-19 who are at high risk for disease progression. In addition, our study provides evidence to suggest that greater benefits can be gained from treating such patients within the first 5 days from illness onset, which included reduced hospital admission and less need for any supplemental oxygen.

To our knowledge, this is the first study performed in a non-selected group of patients specifically focusing on factors associated with the receipt of early bamlanivimab and etesevimab combination therapy and the effects of early treatment on clinical outcomes. Our study includes a relatively large sample size of consecutive patients across three different hospitals and can therefore be considered representative for the current clinical practice in mild and moderate COVID-19.

Bamlanivimab and etesevimab are two monoclonal antibodies that are specifically directed against different but overlapping receptor binding sites of the spike protein of SARS-CoV-2, thus blocking its attachment to the human ACE2 receptor [10,11]. Previous studies evaluating bamlanivimab and etesevimab administered together have demonstrated that such combination significantly decreased SARS-CoV-2 log viral load as well as the need for hospital admission [12,13], leading to their approval from the EUA by the Food and Drug Administration for the treatment of mild and moderate COVID-19 in the outpatient setting [16]. Nevertheless, post-marketing information is very scarce [19–23], and at present, data regarding the correct timing for BEC infusion are lacking.

To the best of our knowledge, this study is the first to report the clinical use of bamlanivimab together with etesevimab in daily clinical practice, a few months after the drugs have been introduced in Italy. In our experience, the rate of hospital admission after BEC infusion was low (11.0%) and similar to the results obtained in other previous clinical experiences focusing on bamlanivimab alone, in which the percentage of hospital admission was reported to be up to 10% of the cases [20–23]. The reduction in the need for subsequent health resource utilization remained low despite the higher proportion of older persons with comorbidities included in the present study [20–23].

We are also the first to demonstrate that time to monoclonal antibodies administration, defined as the time from symptoms onset to monoclonal antibodies infusion, may have an important impact on clinical outcomes. Based on our experience, a larger reduction
in the requirement of any supplemental oxygen and hospital admission could be seen in patients who received early (<5 days) monoclonal antibodies. Accordingly, we suggest that monoclonal antibodies treatment should be started as soon as the diagnosis of SARS-CoV-2 has been established, theoretically within the first five days. Importantly, we should acknowledge that treatment bias is unlikely to explain our findings, as patients with multiple and severe underlying diseases were more likely to receive early BEC infusion.

Translating the main results of our study into clinical practice may be challenging; however, we believe that strategies aimed at early COVID-19 diagnosis and rapid access to monoclonal antibody therapies should be pursued [24]. Among them, infusion centers, pop-up sites or in-home visits should be considered and may be safer from a public health perspective (because of the reduced risk of potentially spreading SARS-CoV-2 in the community) while offering more convenience to the patient. In addition, if future studies will support our findings, we believe that early treatment with monoclonal antibodies should gather similar policy attention to that applied for early antiviral treatment for pandemic influenza [25].

The main limitation of our study is the retrospective analysis of the effect of bamlanivimab and etesevimab combination treatment timing on clinical outcomes, with the potential for residual confounding. Moreover, our study did not include information about the COVID-19 variants [26] as well as data on SARS-CoV-2 vaccination, which could have a significant impact on the clinical evolution of the patients.

5. Conclusions

In conclusion, this real-world study adds to the record of the benefits of bamlanivimab and etesevimab combination for patients with mild or moderate COVID-19 by demonstrating that earlier interventions increased treatment efficacy. Since monoclonal antibodies are relatively safe drugs [12,13], we encourage their early use among all patients with mild–moderate COVID-19 at risk for complications.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/jcm10204682/s1, Table S1: Description of patients who died after BEC infusion.

Author Contributions: Conceptualization, M.B. (Matteo Bassetti), A.V. and E.B.; methodology, M.B. (Matteo Bassetti) and A.V.; validation, M.B. (Matteo Bassetti) and A.V.; investigation, A.V. and E.B.; resources, A.V., G.C., E.B., L.M., A.S.B., M.B. (Marco Berruti), L.B., D.B., A.B., C.D., D.R.G., T.K.E., A.S. (Ambra Scintu), M.M., B.R., C.R., A.S. (Andrea Stimamiglio), L.T., P.P., S.A. and M.B. (Matteo Bassetti); data curation, M.B. (Matteo Bassetti), A.V. and E.B.; writing—original draft preparation, A.V. and M.B. (Matteo Bassetti); writing—review and editing, A.V. and M.B. (Matteo Bassetti). All authors have read and agreed to the published version of the manuscript.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Institutional Review Board Statement: The study protocol was approved by the Ethics Committee of Liguria Region (N.CER Liguria 114/2020-ID10420). Written informed consent was provided by all participants in the study.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: Outside of the submitted work, M Bassetti has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, Astellas, AstraZeneca, Basilea, Bayer, BioMérieux, Cidara, Correvio, Cubist, Menarini, Molteni, MSD, Nabriva, Paratek, Pfizer, Roche, Shionogi, Tetraphase, Thermo Fisher and The Medicine Company. Outside of the submitted work, D R Giacobbe reports honoraria from Stepstone Pharma GmbH and unconditional grants from MSD Italia and Correvio Italia. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter.
or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

1. Vena, A.; Giacobbe, D.R.; Di Biagio, A.; Mikulska, M.; Taramasso, L.; De Maria, A.; Ball, L.; Brunetti, I.; Loconte, M.; Patroniti, N.A.; et al. Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. Clin. Microbiol. Infect. 2020, 26, 1537–1544. [CrossRef] [PubMed]

2. Stokes, E.K.; Zambrano, L.D.; Anderson, K.N.; Marder, E.P.; Raz, K.M.; El Burai Felix, S.; Tie, Y.; Fullerton, K.E. Coronavirus Disease 2019 Case Surveillance—United States, January 22–May 30, 2020. Morb. Mortal. Wkly. Rep. 2020, 69, 759–765. [CrossRef] [PubMed]

3. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; Barnaby, D.P.; Becker, L.B.; Chelico, J.D.; Cohen, S.L.; et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020, 323, 2052–2059. [CrossRef] [PubMed]

4. Nakeshbandi, M.; Maini, R.; Daniel, P.; Rosengarten, S.; Parmar, P.; Wilson, C.; Kim, J.M.; Oomen, A.; Mecklenburg, M.; Salvani, J.; et al. The impact of obesity on COVID-19 complications: A retrospective cohort study. Int. J. Obes. 2020, 44, 1832–1837. [CrossRef] [PubMed]

5. Available online: https://gis.cdc.gov/grasp/covidnet/COVID19_5.html (accessed on 7 June 2021).

6. Docherty, A.B.; Harrison, E.M.; Green, C.A.; Hardwick, H.E.; Pius, R.; Norman, L.; Holden, K.A.; Read, J.M.; Donneling, F.; Carson, G.; et al. Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ 2020, 369, m1985. [CrossRef]

7. Lighter, J.; Phillips, M.; Hochman, S.; Sterling, S.; Johnson, D.; Francois, F.; Stachel, A. Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. Clin. Infect. Dis. 2020, 71, 896–897. [CrossRef]

8. Available online: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-evidence-table.html (accessed on 9 April 2020).

9. Wankowicz, P.; Szylinska, A.; Rotter, I. Insomnia, Anxiety, and Depression Symptoms during the COVID-19 Pandemic May Depend on the Pre-Existing Health Status Rather than the Profession. Brain Sci. 2021, 11, 1001. [CrossRef]

10. Jones, B.E.; Brown-Augsburger, P.L.; Corbett, K.S.; Westendorf, K.; Davies, J.; Cujec, T.P.; Wiethoff, C.M.; Blackbourne, J.L.; Heinz, B.A.; Foster, D.; et al. The Neutralizing Antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. Transl. Med. 2021, 13, eabf1906. [CrossRef]

11. Shi, R.; Shan, C.; Duan, X.; Chen, Z.; Liu, P.; Song, J.; Song, T.; Bi, X.; Han, C.; Wu, L.; et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 2020, 584, 120–124. [CrossRef]

12. Gottlieb, R.L.; Nirula, A.; Chen, P.; Boscia, J.; Heller, B.; Morris, J.; Huhn, G.; Cardona, J.; Mocherla, B.; Stosor, V.; et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA 2021, 325, 632–644. [CrossRef]

13. Group, A.-T.L.-C.S.; Lundgren, J.D.; Grund, B.; Barakuskas, C.E.; Holland, T.L.; Gottlieb, R.L.; Sandkovsky, U.; Brown, S.M.; Knowlton, K.U.; Self, W.H.; et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N. Engl. J. Med. 2021, 384, 905–914. [CrossRef]

14. Jin, Y.; Yang, H.; Ji, W.; Wu, W.; Chen, S.; Zhang, W.; Duan, G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 2020, 12, 372. [CrossRef]

15. Samudrala, P.K.; Kumar, P.; Choudhary, K.; Thakur, N.; Wadekar, G.S.; Dayaramani, R.; Agrawal, M.; Alexander, A. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur. J. Pharmacol. 2020, 883, 173375. [CrossRef] [PubMed]

16. Eli Lilly and Company. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab [CrossRef] [PubMed]

17. Samudrala, P.K.; Kumar, P.; Choudhary, K.; Thakur, N.; Wadekar, G.S.; Dayaramani, R.; Agrawal, M.; Alexander, A. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur. J. Pharmacol. 2020, 883, 173375. [CrossRef] [PubMed]

18. Gandhi, R.T.; Lynch, J.B.; Del Rio, C. Mild or Moderate Covid-19. JAMA 2020, 323, 1757–1766. [CrossRef] [PubMed]

19. Dale, A.P.; Hudson, M.; Cullen, T.; Ellingson, K.; Davis, K.; Armanta, D.; Friebus, H.; Currie, C.; Bhattarai, R.; Brady, S.; et al. Administration of Bamlanivimab to Skilled Nursing Facility Residents During a COVID-19 Outbreak, January–February 2021, Arizona. J. Am. Med. Dir. Assoc. 2021, 13, 612–632. [CrossRef]

20. Karr, E.; Chung, T.; Burton, K.; Markert, R.; Kelly, D. Bamlanivimab Use in a Military Treatment Facility. Mil. Med. 2021, usab188. [CrossRef]

21. Alam, M.M.; Mahmud, S.; Aggarwal, S.; Fathima, S.; Al Mab, N.; Shibli, M.S.; Haque, S.M.; Mahmud, S.; Ahmed, Z. Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study. Cureus 2021, 13, e14933. [CrossRef] [PubMed]

22. Kumar, R.N.; Wu, E.L.; Stosor, V.; Moore, W.J.; Achenbach, C.; Ison, M.G.; Angarone, M.P. Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study. Clin. Infect. Dis. 2021, ciab305. [CrossRef] [PubMed]

23. Dhand, A.; Lobo, S.A.; Wolfe, K.; Feola, N.; Nabors, C. Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience. Clin. Transpl. 2021, 35, e14245. [CrossRef] [PubMed]
24. Ning, L.; Abagna, H.B.; Jiang, Q.; Liu, S.; Huang, J. Development and application of therapeutic antibodies against COVID-19. *Int. J. Biol. Sci.* 2021, 17, 1486–1496. [CrossRef] [PubMed]

25. Kumar, A. Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): Speed is life. *J. Antimicrob. Chemother.* 2011, 66, 959–963. [CrossRef] [PubMed]

26. Lohr, B.; Niemann, D.; Verheyen, J. Bamlanivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient. *Clin. Infect. Dis.* 2021, ciab392. [CrossRef] [PubMed]